We’re thrilled to share the news that our client’s product, the Oraya IRay® Radiotherapy System, has won Silver in the 2015 Annual Medical Design Excellence Awards (MDEA) in the Radiological and Electromechanical Devices category.
Bridge worked in close collaboration with the team at Oraya Therapeutics, Inc. to design and engineer the IRay System from conception to commercialization. The product treats wet age-related macular degeneration (AMD), the leading cause of blindness in those over 65 in the industrialized world, and reflects a significant breakthrough treatment approach.
“The success of any innovative product in the start-up medical world is a combination of the foresight of the founders, the effectiveness of their core technology, and the people they pick to help make it a reality,” said Bridge Design President Bill Evans. “We are honored to have been chosen as Oraya‘s design partner and glad that our contribution to the usability and customer appeal has helped Oraya achieve rapid adoption. Oraya brought us into their fold, integrating us with their technical and marketing teams. From this teamwork comes the product you see. It is rewarding for our designers to be involved in such vision-maintaining therapy, and we wish Oraya well as they expand into new treatment sites.”
Bridge conducted extensive ergonomic studies to gain a clear understanding of physicians’ and patients’ needs, and to inform the development of the product for an international market. Streamlined, easy operator steps that could reduce procedure time and increase overall patient comfort were also vital to the design.
MDEA award-winning products excel in 5 areas: manufacturing and technological innovation; design and engineering advancements; patient benefits; business benefits; and overall improvement to healthcare industry.
“We, alongside our partner Bridge Design, are honored to be recognized with this prestigious award,” said Jim Taylor, president and CEO of Oraya Therapeutics. “Our goal in designing and developing the IRay system was to offer ophthalmologists and their patients an innovative, comfortable and non-invasive treatment option for wet AMD to reduce injections while maintaining vision. We believe that physician ease-of-use and patient comfort have played a significant role in the rapid adoption of Oraya Therapy in Europe and its continued integration into standard clinical care.”
The IRay® Radiotherapy SystemSystem stereotactically delivers low-voltage X-rays for the treatment of wet age-related macular degeneration (AMD). The system’s relatively small footprint is designed for installation in a clinic or hospital, without the need for added room shielding, and to be easy for the trained ophthalmologist to operate. The key proprietary elements of the system consist of a low-energy x-ray tube, a self-contained automated beam positioning system, Oraya Therapy software, the I-Guide™ eye stabilization device and an eye tracking system. Combining these elements into a product that would be attractive as well as providing reliability and efficiency with patient workflow was critical.
Oraya therapy is available at 11 sites in three countries including the United Kingdom, Germany and Switzerland, and additional sites are in active planning stages. The IRay system is CE marked in Europe and is an investigational device not available for sale in the United States.